IDEC-C2B8 (Rituximab) Liệu Pháp Kháng Thể Đơn Dòng Kháng CD20 Trong Điều Trị Bệnh Nhân U Lympho Không Hodgkin Đã Tái Phát Thể Nhẹ
Tóm tắt
Từ khóa
#IDEC-C2B8 #Rituximab #kháng thể đơn dòng #CD20 #u lympho không Hodgkin #pha II #điều trị tái phát #hóa trị liệu #nhạy cảm với điều trị #tác dụng phụ.Tài liệu tham khảo
Horning, 1994, Treatment approaches to the low-grade lymphomas., Blood, 83, 881, 10.1182/blood.V83.4.881.881
Bierman, 1997, High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma., J Clin Oncol, 15, 445, 10.1200/JCO.1997.15.2.445
Miller, 1982, Treatment of B cell lymphoma with monoclonal anti-idiotype antibody., N Engl J Med, 306, 517, 10.1056/NEJM198203043060906
Meeker, 1985, A clinical trial of anti-idiotype therapy for B cell malignancy., Blood, 65, 1349, 10.1182/blood.V65.6.1349.bloodjournal6561349
Brown, 1989, Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon., Blood, 73, 651, 10.1182/blood.V73.3.651.651
Maloney, 1992, Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: The addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells., Blood, 80, 1502, 10.1182/blood.V80.6.1502.1502
Press, 1987, Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas., Blood, 69, 584, 10.1182/blood.V69.2.584.584
Amlot, 1993, A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy., Blood, 82, 2624, 10.1182/blood.V82.9.2624.2624
Conry, 1995, Phase I trial of an anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: Effect of an intensive schedule of administration., J Immunother Emphasis Tumor Immunol, 18, 231, 10.1097/00002371-199511000-00004
Stone, 1996, A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma., Blood, 88, 1188, 10.1182/blood.V88.4.1188.bloodjournal8841188
Kaminski, 1993, Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody., N Engl J Med, 329, 459, 10.1056/NEJM199308123290703
Kaminski, 1996, Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma., J Clin Oncol, 14, 1974, 10.1200/JCO.1996.14.7.1974
Knox, 1996, Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma., Clin Cancer Res, 2, 457
Press, 1993, Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support., N Engl J Med, 329, 1219, 10.1056/NEJM199310213291702
Press, 1995, Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas., Lancet, 346, 336, 10.1016/S0140-6736(95)92225-3
Reff, 1994, Depletion of B cells in vivo by a chimeric mouse numan monoclonal antibody to CD20., Blood, 83, 435, 10.1182/blood.V83.2.435.435
Maloney, 1994, Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma., Blood, 84, 2457, 10.1182/blood.V84.8.2457.2457
Anderson, 1984, Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation., Blood, 63, 1424, 10.1182/blood.V63.6.1424.1424
Dillman, 1986, Continuous infusion of T101 monoclonal antibody in chronic lymphocytic leukemia and cutaneous T-cell lymphoma., J Biol Resp Mod, 5, 394
Writing, 1982, National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage., Cancer, 49, 2112, 10.1002/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2
López-Guillermo, 1994, Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma [see comments]., J Clin Oncol, 12, 1343, 10.1200/JCO.1994.12.7.1343
Tedder, 1994, CD20: A regulator of cell-cycle progression of B lymphocytes., Immunol Today, 15, 450, 10.1016/0167-5699(94)90276-3
Tedder, 1986, Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes., Eur J Immunol, 16, 881, 10.1002/eji.1830160802
van Besien, 1995, Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: The case for aggressive management., J Clin Oncol, 13, 1096, 10.1200/JCO.1995.13.5.1096
Redman, 1002, Phase II trial of fludarabine phosphate in lymphoma: An effective new agent in low-grade lymphoma., J Clin Oncol, 10, 790, 10.1200/JCO.1992.10.5.790
Hochster, 1992, Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: Results of an Eastern Cooperative Oncology Group study., J Clin Oncol, 10, 28, 10.1200/JCO.1992.10.1.28
Falkson, 1996, Fludarabine: A phase II trial in patients with previously treated low-grade lymphoma., Am J Clin Oncol, 19, 268, 10.1097/00000421-199606000-00012
Hoffman, 1994, 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma., J Clin Oncol, 12, 788, 10.1200/JCO.1994.12.4.788
Kay, 1992, 2-Chlorodeoxyadenosine treatment of low-grade lymphomas., J Clin Oncol, 10, 371, 10.1200/JCO.1992.10.3.371